Latest Headlines

Latest Headlines

Sanofi names Gary Nabel chief scientific officer for global R&D

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Cancer drug developer MethylGene raises $34.5M

Canada's MethylGene is raising $34.5 million through the private placement of shares and warrants to fund mid-stage trials of two oncology drugs. Previous investors ProQuest Investments III and Fonds

Celgene terminates MethylGene licensing deal

MethylGene announced that Celgene has terminated their licensing agreement for oncology histone deacetylase inhibitors, including MGCD0103. As a result, MethylGene will reacquire the rights to these

FDA puts partial clinical hold on MethylGene program

Canada's MethylGene says that as a result of its voluntary decision to halt enrollment in a new drug study, the FDA has put a partial clinical hold on its lead development program in cancer. The

ALSO NOTED: CFOs are pharma's new power players; Progen axes staff in restructuring; MethylGene inks collaboration deal;and muc

> Australia's Progen is laying off workers in a restructuring that includes outsourcing the commercial manufacture of PI-88.

ALSO NOTED: Dynogen goes public; Alpharma sells ingredients unit for $395M; Arizona launches new venture fund; and much more...

> Dynogen Pharmaceuticals is going public in a buyout deal with Apex Bioventures Acquisition Corp. Dynogen shareholders will initially receive $98 million in the deal, with Dynogen merging with a

ALSO NOTED: GSK cuts 5,000 jobs; Codexis opens Singapore lab; Reliant sets IPO terms;and much more...

> The closure of a GlaxoSmithKline's Puerto Rican plant has kicked off the plan to cut 5,000 jobs.